

Please complete this **entire** form and fax it to: **866-940-7328**. If you have questions, please call **800-310-6826**.
This form contains multiple pages. Please complete all pages to avoid a delay in our decision.
Allow at least 24 hours for review.

Section A – Member Information

First Name:	Last Name:	Member ID:
Address:		
City:	State:	ZIP Code:
Phone:	DOB:	Allergies:
Primary Insurance:	Policy #:	Group #:

Is the requested medication New or Continuation of Therapy? If continuation, list start date: _____
 Is this patient currently hospitalized? Yes No If recently discharged, list discharge date: _____

Section B - Physician Information

First Name:	Last Name:	M.D./D.O.
Address:		City: State: ZIP code:
Phone:	Fax:	NPI #: Specialty:
Office Contact Name / Fax attention to:		

Section C - Medical Information

Medication:	Strength:
Directions for use:	Quantity:
Diagnosis (Please be specific & provide as much information as possible):	ICD-10 CODE:
Is this member pregnant? <input type="checkbox"/> Yes <input type="checkbox"/> No If yes, what is this member's due date? _____	

Section D – Previous Medication Trials

Medications	Strength	Directions	Dates of Therapy	Reason for failure / discontinuation

Section E – Additional information and Explanation of why preferred medications would not meet the patient's needs
Please refer to www.uhccommunityplan.com for a list of preferred alternatives

Member First name:	Member Last name:	Member DOB:
---------------------------	--------------------------	--------------------

Clinical and Drug Specific Information

All Requests:

- Does the patient have a diagnosis of cystic fibrosis (CF)? Yes No
If no, list diagnosis: _____
- Has the physician submitted laboratory results confirming the patient is homozygous for the F508del mutation in the CFTR gene? Yes No
- Is the patient at least 6 years of age or older? Yes No
- Is Orkambi prescribed by or in consultation with a specialist affiliated with a CF care center? Yes No

Continuation of Therapy:

- Does the provider attest that the patient has achieved a clinically meaningful response while on Orkambi therapy to any of the following? Yes No (check which apply)
 - Lung function as demonstrated by percent predicted expiratory volume in 1 second (ppFEV1)
 - Body mass index (BMI)
 - Pulmonary exacerbations
 - Quality of life as demonstrated by Cystic Fibrosis Questionnaire-Revised (CFQ-R) respiratory domain score

Physician Signature: _____ **Date:** _____

Confidentiality Notice: This transmission contains confidential information belonging to the sender and UnitedHealthcare. This information is intended only for the use of UnitedHealthcare. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or action involving the contents of this document is prohibited. If you have received this telecopy in error, please notify the sender immediately.

Website: uhcommunityplan.com